Continued treatment with thienopyridine , as compared with placebo , reduced the rates of stent thrombosis ( @ % vs. @ % ; hazard ratio , @ -LSB- @ % confidence interval -LCB- CI -RCB- , @ to @ -RSB- ; P < @ ) and major adverse cardiovascular and cerebrovascular events ( @ % vs. @ % ; hazard ratio , @ -LSB- @ % CI , @ to @ -RSB- ; P < @ ) .